Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Mar
09
First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
Jan
11
Our Wish in 2024: Renewed Hope for People Living with Chronic Inflammatory Diseases
Nov
14
UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
Oct
18
BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
Aug
01
Evolving Expectations for Dermatological Conditions
Dec
23
UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab
Dec
07
The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis
Nov
22
UCB Submits Response to FDA Complete Response Letter for Bimekizumab
Mar
26
New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting
